Lilotomab

{{Short description|Murine monoclonal antibody against CD37}}

{{Infobox drug

| drug_name =

| type = mab

| mab_type = mab

| source = o

| target = CD37

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_AU_comment =

| legal_CA =

| legal_DE =

| legal_NZ =

| legal_UK =

| legal_US =

| legal_UN =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 1453362-55-4

| CAS_supplemental = {{CAS|1453362-90-7}} (lutetium (¹⁷⁷Lu) lilotomab satetraxetan)

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 58I6YNR7BV

| ATCvet =

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank =

| KEGG = D12125

| synonyms = Tetulomab, HH1

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37,{{cite journal|title=Recommended INN List 74|journal=WHO Drug Information|date=2015|volume=29|issue=3|url=https://www.who.int/medicines/publications/druginformation/issues/74_INN_List.pdf?ua=1}} a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.{{cite journal | vauthors = Robak T, Robak P | title = Anti-CD37 antibodies for chronic lymphocytic leukemia | journal = Expert Opinion on Biological Therapy | volume = 14 | issue = 5 | pages = 651–61 | date = May 2014 | pmid = 24555705 | doi = 10.1517/14712598.2014.890182 | s2cid = 19987961 }}

As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. This compound is called ¹⁷⁷Lu-HH1 or lutetium (¹⁷⁷Lu) lilotomab satetraxetan (trade name Betalutin).{{cite web |title= Lutetium (177lu) lilotomab satetraxetan - Nordic Nanovector |url=http://adisinsight.springer.com/drugs/800037665| work = Adis Insight | publisher = Springer Nature Switzerland AG |access-date=1 September 2016}} As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.{{cite web|title=EudraCT Number: 2011-000033-36|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-000033-36/CZ|publisher=EU Clinical Trials Registry|quote=Treatment of lymphoma with targeted internal radiation therapy (Betalutin)}}

File:Lutetium-177 satetraxetan.svg

{{clear left}}